Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-17

Clinical Trial Update: Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial investigating maribavir for resistant or refractory CMV infections in transplant recipients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Maribavir (maribavir)

Snippet

Sponsor: Shire | Conditions: Cytomegalovirus (CMV) | Phase 2 | Status: COMPLETED | Results posted: 2015-12-17